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The new psychoactive substances (NPS) market continues to be very dynamic.
A large number of compounds belonging to diverse chemical groups continue to
emerge. This makes their detection in biological samples challenging for clinical and
forensic toxicologists. Knowledge of the metabolic fate of NPS is crucial for developing
comprehensive screening procedures. As human studies are not feasible due to
ethical concerns, the current study aimed to compare the NPS’ metabolic pattern in
incubations with pooled human liver S9 fraction (pHLS9), human liver HepaRG cells,
and zebrafish larvae. The latter model was recently shown to be a promising preclinical
surrogate for human hepatic metabolism of a synthetic cannabinoid. However, studies
concerning other NPS classes are still missing and therefore an amphetamine-based
N-methoxybenzyl (NBOMe) compound, a synthetic cathinone, a pyrrolidinophenone
analog, a lysergamide, as well as another synthetic cannabinoid were included in the
current study. Liquid chromatography coupled to Orbitrap-based high-resolution tandem
mass spectrometry was used to analyze metabolic data. Zebrafish larvae were found to
produce the highest number of phase I but also phase II metabolites (79 metabolites in
total), followed by HepaRG cells (66 metabolites). Incubations with pHLS9 produced the
least metabolites (57 metabolites). Furthermore, the involvement of monooxygenases
and esterases in the metabolic phase I transformations of 4F-MDMB-BINACA was
elucidated using single-enzyme incubations. Several cytochrome P450 (CYP) isozymes
were shown to contribute, and CYP3A5 was involved in all CYP-catalyzed reactions,
while amide and ester hydrolysis were catalyzed by the human carboxylesterase (hCES)
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isoforms hCES1b and/or hCES1c. Finally, metabolites were compared to those present in
human biosamples if data were available. Overall, the metabolic patterns in HepaRG cells
provided the worst overlap with that in human biosamples. Zebrafish larvae experiments
agreed best with data found in human plasma and urine analysis. The current study
underlines the potential of zebrafish larvae as a tool for elucidating the toxicokinetics of
NPS in the future.
Keywords: drugs of abuse, zebrafish, metabolism study, isozymemapping, LC-HRMS/MS, toxicological screening
INTRODUCTION
New psychoactive substances (NPS) are a global issue posing
a remarkable challenge to drug policy and a risk to public
health. The number of deaths attributed to NPS dramatically
increased during the last years, and most NPS appeared to induce
more severe adverse effects than classic drugs such as heroin,
cannabis, and amphetamine (Kronstrand et al., 2018). Symptoms
associated with NPS intake might range from central nervous
system toxicity leading to seizures, acute psychosis, aggression,
to cardiotoxicity, and liver toxicity resulting in, e.g., arrhythmias
and system failures (Kronstrand et al., 2018). NPS products are
easily available, mainly via Internet shops selling new compounds
as so-called “legal highs” or “research chemicals” (Brandt et al.,
2014). Little or no scientific information are available about the
effects of NPS and how best to counteract them. Besides, users are
often unaware of the content and the dosage of the psychoactive
substances contained in NPS products and potentially exposed to
additional serious health risks (UNODC, 2019).
Furthermore, the NPS market is very dynamic and
characterized by the large numbers of new substances belonging
to several chemical groups (EMCDDA, 2019; UNODC, 2019).
Between 2009 and 2016, 739 different NPS were reported to the
United Nations Office on Drugs and Crime’s Early Warning
Advisory (UNODC, 2019). The diversity of compounds available
on the market makes the detection of NPS in biological samples
challenging for clinical and forensic toxicologists (Wagmann
and Maurer, 2018). High-resolution mass spectrometry “is on
the way to become the gold standard in non-targeted screening
procedures due to its high flexibility, sensitivity, and selectivity”
(Maurer and Meyer, 2016; Meyer and Maurer, 2016). The matrix
of choice for comprehensive screening purposes is urine, which
can be obtained non-invasively, provides large volumes, and
the drugs as well as their metabolites are usually concentrated
(Peters, 2014). However, lipophilic NPS are often extensively
metabolized and the analytical strategy should also be focused
on metabolites particularly in urine screening (Wagmann and
Maurer, 2018). Thus, metabolism studies are mandatory for
developing comprehensive screening methods. Metabolites
may be identified in samples obtained from authentic cases.
However, authentic human biosamples are often not available
and controlled human studies are not feasible due to ethical
concerns and lack of preclinical safety data (Meyer, 2016). To
overcome this issue, metabolites can be generated using various
in vitro or in vivo models (Meyer, 2018; Wagmann and Maurer,
2018; Diao and Huestis, 2019). Zebrafish (Danio rerio) has
become a popular model organism. It shares morphological,
physiological, and histological characteristics with mammals.
For instance, several cytochrome P450 (CYP) enzymes in
zebrafish have direct orthologs in humans. It is therefore
expected that zebrafish drug metabolism may be similar to that
in mammals (De Souza Anselmo et al., 2017). Not only the
adult zebrafish, but also zebrafish larvae were used to generate
xenobiotic metabolites (Diao and Huestis, 2019). The larvae
are not considered as animals until 5 days post-fertilization
(dpf) according to the European Directive 2010/63/EU. Despite
this, they provide benefits of intact organisms (EU, 2010; Van
Wijk et al., 2016). In 2019, Richter et al. used the new synthetic
cannabinoid 7′N-5F-ADB (also known as 5F-MDMB-P7AICA
and methyl 2-[1-(5-fluoropentyl)-1H-pyrrolo[2,3-b]pyridine-
3-carboxamido]-3,3-dimethylbutanoate) to further develop the
zebrafish larvae model, with the aim to be used as a preclinical
surrogate for human hepatic NPS metabolism (Richter et al.,
2019a). Results obtained with the larvae model were then
compared to those of established in vitro incubations using
pooled human liver S9 fraction (pHLS9) or the human hepatoma
cell line HepaRG. Data of the model systems were also compared
to human urinary metabolites (Richter et al., 2019a). Incubations
with pHLS9 produced the lowest number of metabolites, while
zebrafish larvae and HepaRG cell incubations provided the
most comprehensive spectrum of human urinary 7′N-5F-ADB
metabolites (Richter et al., 2019a,b). The authors concluded that
zebrafish larvae seemed to be a promising model for studying the
toxicokinetics of NPS, but further studies comparing different
NPS classes were needed (Richter et al., 2019a). Therefore, the
aim of the current study was to evaluate five NPS of different
classes in a similar manner. Their chemical structures are
given in Figure 1. The amphetamine-based NBOMe 3,4-DMA-
NBOMe (also known as 3,4-dimethoxyamphetamine-NBOMe
and 1-[3,4-dimethoxy]-N-[ortho-methoxybenzyl]propane-
2-amine), the synthetic cathinone ephylone (also known as
N-ethylnorpentylone and N-ethylpentylone), the synthetic
cannabinoid 4F-MDMB-BINACA (also known as methyl
2-[1-(4-fluorobutyl)-1H-indazole-3-carbonyl]amino-3,3-
dimethylbutanoate and 4-fluoro MDMB-BUTINACA),
the pyrrolidinophenone analog 4F-PHP (also known as
4-fluoro-alpha-pyrrolidinohexiophenone, 4-fluoro-alpha-
pyrrolidinohexanophenone, 4-F-α-PHP, and 4F-alpha-PHP),
and the lysergamide 1P-LSD (1-propionyl-d-lysergic acid
diethylamide) were included. The five NPS were already shown
to be extensively metabolized and therefore suitable for the
current comparative metabolism study (Caspar et al., 2018b;
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FIGURE 1 | Chemical structures of the five new psychoactive substances included in the current study.
Haschimi et al., 2019; Krotulski et al., 2019; Wagmann et al.,
2019b,c). Caspar et al. used pHLS9 incubations and rat urine to
investigate the metabolism of 3,4-DMA-NBOMe (Caspar et al.,
2018b; Wagmann et al., 2019b,c). Wagmann et al. identified
metabolites of ephylone and 4F-PHP in human blood and urine
as well as in pHLS9 incubations (Caspar et al., 2018b; Wagmann
et al., 2019b,c). The metabolic fate of 4F-MDMB-BINACA was
investigated using human biosamples and incubations with
pooled human liver microsomes (pHLM) (Haschimi et al., 2019;
Krotulski et al., 2019) and results of in vitro incubations with
pHLS9 and 1P-LSD were also described (Caspar et al., 2018b;
Wagmann et al., 2019b,c).
In the current study, liquid chromatography coupled to
Orbitrap-based high-resolution tandem mass spectrometry (LC-
HRMS/MS) was used to analyze metabolic data after incubations
with zebrafish larvae and HepaRG cells. The metabolites were
compared to those detected in pHLS9 incubations, which were
already described for four out of five compounds (Caspar
et al., 2018b; Wagmann et al., 2019b,c). 4F-MDMB-BINACA
pHLS9 incubations should be done in this study. The detected
metabolites were compared to those in human biosamples if
data were available. To further extend the knowledge about
the metabolism of 4F-MDMB-BINACA, monooxygenases and
esterases involved in its phase I metabolism should be identified
in activity screenings.
MATERIALS AND METHODS
Reagents, Chemicals, and Enzymes
4F-MDMB-BINACA was provided by the EU-funded project
ADEBAR (IZ25-5793-2016-27) for research purposes. 3,4-DMA-
NBOMe, ephylone, 4F-PHP, and 1P-LSD were available
from previous studies (Caspar et al., 2018b; Wagmann
et al., 2019b,c). The hydrochloride of racemic 3,4-DMA-
NBOMe was provided by the State Bureau of Criminal
Investigation Schleswig-Holstein (Kiel, Germany) for research
purposes, ephylone and 4F-PHP were obtained from an
online vendor of NPS based in the Netherlands, and 1P-
LSD was provided by Synex Synthetics (Maastricht, the
Netherlands). The identity as well as purity of the NPS
were confirmed by high-performance liquid chromatography
(HPLC), infrared spectroscopy, and MS/MS. NADP+ was
obtained from Biomol (Hamburg, Germany), trimipramine-
d3 was from LGC (Wesel, Germany), and dithiothreitol,
reduced glutathione, superoxide dismutase, magnesium
chloride (MgCl2), dipotassium hydrogen phosphate (K2HPO4),
potassium dihydrogen phosphate (KH2PO4), Tris hydrochloride,
isocitrate dehydrogenase, isocitrate, 3′-phosphoadenosine-
5′-phosphosulfate (PAPS), S-(5′-adenosyl)-L-methionine
(SAM), dimethyl sulfoxide (DMSO), acetyl coenzyme A,
diazepam-d5, and ammonium formate (analytical grade)
were from Merck KGaA (Darmstadt, Germany). Uridine 5′-
diphospho-glucuronosyltransferase (UGT) reaction mixture
solution A (25mM UDP glucuronic acid), UGT reaction
mixture solution B (250mM Tris–HCl, 40mM MgCl2,
and 0.125 mg/ml alamethicin), pHLS9 (20mg protein/ml),
pHLM (20mg microsomal protein/ml, 330 pmol total
CYP/mg protein), the baculovirus-transfected insect cell
microsomes (Supersomes) containing 1 nmol/ml of the
human complementary DNA-expressed cytochrome P450
(CYP) isozymes CYP1A2, CYP2A6, CYP2B6, CYP2C8,
CYP2C9 (2 nmol/ml), CYP2C19, CYP2D6, CYP2E1 (2
nmol/ml), CYP3A4, CYP3A5 (2 nmol/ml), flavin-containing
monooxygenase 3 (FMO 3, 5mg protein/ml), and recombinant
human carboxylesterases hCES1b, hCES1c, and hCES2 were
obtained from Corning (Amsterdam, the Netherlands). All
enzyme containing preparations were thawed at 37◦C after
delivery, aliquoted, snap-frozen in liquid nitrogen, and stored at
−80◦C until use. Williams Medium E, HPRG670 supplement,
GlutaMAX, cryopreserved and differentiated HepaRG cells,
and 96-well plates coated with type I collagen were obtained
from Life Invitrogen (Darmstadt, Germany). Zebrafish embryos
were obtained from in-house bred adult zebrafish (approval
no. 2.4.1.1-H, Landesamt für Verbraucherschutz, Saarland,
Germany) of the AB wild-type line, and 6-well plates and
96-well plates were obtained from Sarstedt (Nümbrecht,
Germany). Acetonitrile (LC-MS grade), methanol (LC-MS
grade), formic acid (LC-MS grade), and all other reagents
and chemicals (analytical grade) were purchased by VWR
(Darmstadt, Germany).
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Incubations With pHLS9 and
4F-MDMB-BINACA
According to published procedures (Richter et al., 2017b,
2019b; Caspar et al., 2018b; Wagmann et al., 2019b,c),
the final incubation volume per reaction tube was 150 µl,
with a final protein concentration of 2 mg/ml. The given
concentrations represent final concentrations. A preincubation
for 10min at 37◦C with UGT reaction mixture solution B
(containing alamethicin, 25µg/ml), MgCl2 (2.5mM), NADP
+
(0.6mM), isocitrate (2.5mM), isocitrate dehydrogenase (0.8
U/ml), superoxide dismutase (100 U/ml), acetyl coenzyme A
(0.1mM), phosphate buffer (90mM, pH 7.4), and pHLS9 (2
mg/ml) was done. Afterwards, UGT reaction mixture solution
A (containing UDP glucuronic acid, 2.5mM), PAPS (40µM),
SAM (1.2mM), dithiothreitol (1mM), and glutathione (10mM)
were added, as well as 25µM 4F-MDMB-BINACA to start the
reactions. The mixture was incubated for 360min. Total amount
of organic solvent in incubation mixtures was <2% (Chauret
et al., 1998). After 60min, an aliquot of the reaction mixture (60
µl) was transferred in another reaction tube containing 20 µl of
ice-cold acetonitrile to terminate the reactions. The remaining
aliquot (90 µl) was incubated for an additional 300min, and
then the reactions were stopped by adding 30 µl of ice-cold
acetonitrile. Thereafter, the reaction tubes were cooled at −20◦C
for 30min prior to centrifugation at 18,407 × g for 2min. The
supernatants (50 µl) were transferred into autosampler vials,
and 1 µl was injected onto the LC-HRMS/MS system. Control
samples without pHLS9 and blank samples without substrate
were prepared to confirm the absence of non-metabolically
formed and interfering compounds, respectively. All incubations
were performed in duplicate.
In vivo Maximum-Tolerated Concentration
Studies in Zebrafish Larvae
Internal protocols based on published standard methods
(Westerfield, 2007) were used to perform zebrafish husbandry
and the maximum-tolerated concentration (MTC) testing was
based on a previous study (Richter et al., 2019a). Danieau’s
medium [17mM NaCl, 2mM KCl, 0.12mM MgSO4, 1.8mM
Ca(NO3)2, 1.5mM HEPES, pH 7.1–7.3, and 1.2µM methylene
blue] at 28◦C was used to raise zebrafish larvae of the AB wild-
type strain. For MTC testing, 96-well plates were used with 100
µl of medium and one larva per well. Drug exposition was started
4 dpf using 0, 0.01, 0.1, 1, 10, 50, or 100µM final concentrations
of 3,4-DMA-NBOMe, ephylone, 4F-MDMB-BINACA, 4F-PHP,
or 1P-LSD, respectively. The drug exposure in the incubator
at 28◦C lasted 24 h. The final DMSO concentration was 1%
(v/v) for all experiments. Monitoring of the larvae was done
using a LEICA M205 FA stereo microscope (Leica Mikrosysteme
Vertrieb GmbH, Wetzlar, Germany) to detect developmental
defects and/or decreased survival rates. Fifteen larvae were used
for each experiment.
Zebrafish Larvae Exposure
In accordance with a previous study (Richter et al., 2019a)
with minor modifications, substances were administrated to
the zebrafish larvae at 4 dpf via the Danieau’s medium with
final substrate concentrations of 25µM (4F-MDMB-BINACA)
or 100µM (3,4-DMA-NBOMe, ephylone, 4F-PHP, and 1P-LSD),
respectively, and a final DMSO concentration of 1% (v/v). Six-
well plates were used and 10 larvae were placed in each well
containing 2,000µl of Danieau’s medium supplemented with one
of the NPS. After an incubation period of 24 h at 28◦C, the larvae
were collected separated from the surrounding medium. All
larvae of one well (10 larvae) were washed twice with 1,000 µl of
Danieau’s medium. Afterwards, they were euthanized by placing
the tubes in ice water for 15min. After removing the residual
medium, the larvae were snap-frozen in liquid nitrogen followed
by lyophilization and stored at −20◦C until extraction. Twenty
larvae (from two wells) were extracted using 50 µl of methanol,
shaken for 2min, and centrifuged for 2min at 18,407× g. Thirty
microliters of the supernatants was transferred into autosampler
vials and 1 µl was injected onto the LC-HRMS/MS system.
Medium samples without larvae were collected to identify non-
metabolically formed compounds. Blank larvae samples without
the NPS were prepared to confirm the absence of interfering
compounds. All incubations were done in triplicate.
Incubations With HepaRG Cells
Cell culture experiments using differentiated human
hepatocellular carcinoma HepaRG cells were carried out as
recently described (Richter et al., 2019a,c). Cells were handled
under sterile conditions. A laminar flow bench class II (Thermo
Scientific Schwerte, Germany) and an incubator (Binder,
Tuttlingen, Germany) with 95% air humidity and 5% CO2
atmosphere at 37◦C were used. The concentrations given in
the following are final concentrations. Collagen-coated 96-well
plates were used and the HepaRG cells were seeded in a density
of 72,000 cells/well (a 100-µl aliquot cell suspension/well) in
thaw and seed medium, consisting of Williams E medium
supplemented with penicillin (100 U/ml), streptomycin
(100µg/ml), GlutaMAX, and HPRG670. Four hours after cell
seeding, 50 µl of the supernatants was removed from each well.
Afterwards, 50 µl of the thaw and seed medium containing
3,4-DMA-NBOMe, ephylone, 4F-MDMB-BINACA, 4F-PHP,
or 1P-LSD (50 or 500µM resulting in final concentrations
of 25 or 250µM), respectively, was added. Each well also
contained 0.5% (v/v) DMSO. After drug exposure of 24 h, 50
µl of the supernatants was precipitated using the same volume
of acetonitrile containing 0.1% (v/v) formic acid. The mixtures
were vortexed, cooled for 30min at −20◦C, and centrifuged
at 18,407×g for 2min. Eighty microliters of the mixture was
transferred into an autosampler vial and 1 µl was injected onto
the LC-HRMS/MS system. Control samples without substrate
and blank samples without HepaRG cells were prepared in the
same manner to confirm the absence of interfering compounds
or non-metabolically formed compounds, respectively. All
incubations were performed in triplicate.
Monooxygenases Activity Screening of
4F-MDMB-BINACA
According to an established protocol (Wagmann et al., 2016), the
final volume per reaction tube was 50 µl with a final 4F-MDMB-
BINACA concentration of 25µM and enzyme concentrations
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of 50 pmol/ml for CYP1A2, CYP2A6, CYP2B6, CYP2C8,
CYP2C9, CYP2C19, CYP2D6, CYP2E1, CYP3A4, and CYP3A5,
respectively, or 0.25mg protein/ml for FMO3. Furthermore,
the reaction mixture contained 90mM phosphate buffer (pH
7.4), superoxide dismutase (200 U/ml), isocitrate (5mM), MgCl2
(5mM), isocitrate dehydrogenase (0.5 U/ml), and NADP+
(1.2mM). The phosphate buffer was replaced with Tris buffer
(90mM) for incubations with CYP2A6 and CYP2C9 according
to the manufacturer’s recommendation. All incubations were
performed at 37◦C for 30min and terminated by adding 50 µl of
ice-cold acetonitrile. Afterwards, the mixtures were centrifuged
at 18,407×g for 5min, 70 µl of the supernatants was transferred
into autosampler vials, and 1 µl was injected onto the LC-
HRMS/MS system. Positive control incubations were performed
with pHLM (1mgmicrosomal protein/ml), and negative controls
without enzyme were prepared to identify non-metabolically
formed compounds. All incubations were done in duplicate.
Esterases Activity Screening of
4F-MDMB-BINACA
Experiments were performed in accordance with a previous study
(Meyer et al., 2015) with minor modifications. The final volume
per reaction tube was 100 µl with a final 4F-MDMB-BINACA
concentration of 100µM and enzyme concentration of 0.2mg
protein/ml for hCES1b, hCES1c, and hCES2. Incubations with
pHLM and pHLS9 (0.2mg protein/ml, each) were performed in
a similar manner. Additionally, incubations with human plasma
(50 µl pooled human plasma, 40 µl phosphate buffer, and 10
µl substrate) were performed. The reactions were started by
adding the enzyme-containing preparation and terminated with
an equal volume of ice-cold acetonitrile containing diazepam-
d5 (100µM) as an internal standard. Only plasma incubations
were terminated by addition of a three-fold volume of ice-
cold acetonitrile. The reaction mixtures were centrifuged at
18,407×g for 15min, and then supernatants were transferred
to autosampler vials, and 5 µl was injected onto the LC-
HRMS/MS system. Negative control incubations without enzyme
were prepared to identify non-metabolically formed compounds.
All incubations were done in duplicate.
Preparation of Human Biosamples After
Intake of 4F-MDMB-BINACA
Human blood and urine collected after a suspected intake of
drugs of abuse were submitted to the authors’ laboratory for
regular clinical toxicological analysis. The blood sample was
centrifuged, and plasma was separated. The authors’ standard
liquid–liquid extraction for human plasma screening was used
(Maurer et al., 2016). Briefly, 1,000 µl of plasma was mixed
with 100 µl of internal standard (0.01 µg/µl trimipramine-
d3 in methanol) and extracted with 5,000 µl of a mixture of
diethyl ether:ethyl acetate (1:1, v/v) after addition of 2,000 µl of
saturated sodium sulfate solution. Phase separation wasmediated
by centrifugation. The organic layer was transferred into a flask
and evaporated to dryness at 60◦C under reduced pressure.
The aqueous residue was then alkalized with 500 µl of 1M
sodium hydroxide and extracted a second time with 5,000 µl of
the diethyl ether:ethyl acetate mixture. The organic extract was
transferred to the same flask and evaporated as described before.
The combined residues were dissolved in 100 µl of methanol
and transferred into an autosampler vial, and 5 µl was injected
onto the LC-HRMS/MS system. An aliquot of the human urine
sample (100 µl) was prepared according to a previous study by
precipitation with 500µl of acetonitrile (Wissenbach et al., 2011).
The mixture was shaken and centrifuged (18,407×g, 2min).
After transfer of the supernatant into an autosampler vial, it was
evaporated to dryness at 70◦C under a gentle stream of nitrogen.
The residue was dissolved in 50 µl of a mixture of eluent A and
B (see LC-HRMS/MS conditions, 1:1, v/v) and 5 µl was injected
onto the LC-HRMS/MS system.
LC-HRMS/MS Apparatus and Conditions
According to a previous study (Richter et al., 2019a), a Thermo
Fisher Scientific (TF, Dreieich, Germany) Dionex UltiMate
3000 Rapid Separation (RS) UHPLC system with a quaternary
UltiMate 3000 RS pump and an UltiMate 3000 RS autosampler
controlled by the TF Chromeleon software version 6.8 was used.
The LC system was coupled to an Orbitrap-based TF Q-Exactive
Plus equipped with a heated electrospray ionization II (HESI-II)
source. Calibration was done prior to analysis with a Positive Cal
Mix (Supelco, Bellefonte, PA, USA) at a flow rate of 3 µl/min
using a syringe pump. The conditions of the LC system were
as follows: TF Accucore PhenylHexyl column (100 × 2.1mm,
2.6µm particle size); gradient elution with 2mM ammonium
formate solution containing 0.1% (v/v) formic acid (eluent A)
and 2mM ammonium formate solution in acetonitrile/methanol
(50:50, v/v) containing 0.1% (v/v) formic acid, and 1% (v/v) water
(eluent B). The flow rate was set to 0.5 ml/min (0–11.5min) and
0.8 ml/min (11.5–13.5min). The following gradient was used:
0–1.0min hold 1% B, 1–10min to 99% B, 10–11.5min hold
99% B, 11.5–13.5min hold 1% B. The HESI-II source conditions
were as follows: ionization mode, positive; heater temperature,
320◦C; ion transfer capillary temperature, 320◦C; sheath gas, 60
arbitrary units (AU); auxiliary gas, 10AU; spray voltage, 4.00
kV; and S-lens RF level, 50.0. Mass spectrometry experiments
were performed using high-resolution (HR) full scan mode and
a targeted MS2 mode with an inclusion list for each NPS. The
inclusion list contained m/z values of metabolites, which were
likely to be formed for example hydroxy, oxo, carboxy, dealkyl,
demethylenylated, and defluorinated metabolites (phase I) as
well as sulfates and glucuronides (phase II) and combinations
of them. Full scan settings were as follows: resolution, 35,000;
automatic gain control (AGC) target, 3e6; maximum injection
time (IT), 120ms; scan ranges, 3,4-DMA-NBOMe m/z 100–
700, ephylone m/z 200–600, 4F-MDMB-BINACA m/z 150–700,
4F-PHP m/z 200–600, and 1P-LSD m/z 250–700. The settings
for the targeted MS2 mode with the respective inclusion lists
were as follows: resolution, 17,500; AGC target, 2e5; maximum
IT, 250ms; loop count, 5; isolation window, 1.0 m/z; stepped
normalized collision energy (NCE), 17.5, 35, 52.5%; pick others,
enabled. ChemSketch 2018 2.1 (ACD/Labs, Toronto, Canada)
was used to draw the structures of the hypothetical metabolites
and for the calculations of the exact masses. Xcalibur Qual
Browser version 4.1.31.9 (TF) was used for data handling. The
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mass tolerance between calculated and measured mass was
adjusted to 5 ppm. For identification of metabolites, HR full scan
data were screened for potential exact precursor ion (PI) masses
of expected metabolites. Metabolites were tentatively identified
by comparing the corresponding HRMS2 spectrum to that of the
parent compound.
RESULTS AND DISCUSSION
Identification of 4F-MDMB-BINACA Phase
I and II Metabolites in pHLS9 Incubations
Only the reference material of the parent compound 4F-
MDMB-BINACA was available. Therefore, postulated metabolic
transformations could not be confirmed using chemical
standards, and all the metabolites were claimed to be tentatively
identified. This was also true for the other investigated NPS. All
tentatively identified metabolites of 4F-MDMB-BINACA along
with their absolute peak areas in pHLS9 incubations after 1 or 6 h
of incubations are listed in Table 1. The given areas were taken
from one replicate of the pHLS9 incubations (n= 2). The second
replicate provided the same pattern of metabolite abundances.
HRMS2 spectra of the parent compound and the metabolites
discussed in detail in the following are depicted in Figure 2, while
HRMS2 spectra of all other 4F-MDMB-BINACA metabolites
are depicted in the Electronic Supplementary Material (ESM).
The metabolites were sorted by increasing m/z. In case of
isomers with identicalm/z, metabolites were sorted by increasing
retention time. Each metabolite was assigned to a unique
metabolite ID. The calculated exact masses, not the measured
masses, will be used in the following. In total, 15 phase I and
two phase II metabolites of 4F-MDMB-BINACA were detected
in pHLS9 incubations (see Table 2). Haschimi et al. performed
4F-MDMB-BINACA incubations with pHLM instead of pHLS9
without co-substrates of phase II metabolic reactions and
identified 11 phase I metabolites (Haschimi et al., 2019). All these
metabolites were also detected in pHLS9 incubations with one
exception, namely, a 4F-MDMB-BINACA metabolite formed
after ester hydrolysis and hydroxylation of the butyl chain.
The HRMS2 spectrum of 4F-MDMB-BINACA (PI at
m/z 364.2031, C19H27O3N3F
+) showed the subsequent
fragmentation of the ester moiety due to an initial methanol
loss (−32.0262 u, CH4O) forming the fragment ion (FI)
at m/z 332.1769 (C18H23O2N3F
+) followed by a loss of
CO (−27.9949 u), resulting in the FI at m/z 304.1820
(C17H23ON3F
+). The most abundant FI at m/z 219.0928
(C12H12ON2F
+) corresponded to a cleavage of the amide moiety
between the carbonyl carbon atom and the nitrogen atom. The
FI at m/z 237.1034 (C12H14O2N2F
+) represented a mass shift
of +18.0106 u corresponding to the mass of water. Richter et al.
postulated a rearrangement reaction for 5F-ADB potentially
also explaining the current finding. 5F-ADB obtained a similar
structure, but with a fluoro pentyl chain instead of the fluoro
butyl chain of 4F-MDMB-BINACA. Ester cleavage followed by
nucleophilic attack of the oxygen at the indazole nitrogen in
position 2 may lead to cyclization (Richter et al., 2019b). Further
cleavage of the amide bond and the ester bond may result in the
FI atm/z 237.1034. The same shift was detected for the FIs atm/z
145.0396 (C8H5ON
+
2 ) and 163.0502 (C8H7O2N
+
2 ), formed after
cleavage of the amide bond between the carbonyl carbon atom
and the nitrogen atom and elimination of the fluoro butyl chain.
Due to the large number of metabolites tentatively identified
in this study, only some 4F-MDMB-BINACA metabolites with
fragmentation patterns that were representative for the other
metabolites could be described in detail. After ester hydrolysis
(MB8, PI at m/z 350.1874, C18H25O3N3F
+), an initial loss of
water (−18.0105 u, H2O) was observed resulting in the FI at
m/z 332.1769 (C18H23O2N3F
+), instead of a loss of methanol
as described for the parent compound 4F-MDMB-BINACA, but
also followed by a loss of CO. A similar fragmentation pattern was
already described for other carboxylic acids (Niessen and Correa,
2016; Wagmann et al., 2019a). All other FIs were the same as
those detected in the HRMS2 spectrum of 4F-MDMB-BINACA.
Two metabolites with the PI at m/z 366.1824 (MB13,
MB14, C18H25O4N3F
+) were identified as products of
ester hydrolysis plus hydroxylation. Both spectra obtained
an initial water loss resulting in the FI at m/z 348.1718
(C18H23O3N3F
+) supporting the assumption of prior ester
hydrolysis. Furthermore, the mass shift of +15.9949 u between
the FI at m/z 320.1769 (C17H23O2N3F
+) and 304.1820
(C17H23ON3F
+) in the spectrum of the parent compound
indicated an additional oxygen atom at the fluoro butyl
chain, the indazole ring, or the tert-butyl group. In case
of MB13, FIs at m/z 237.1034, 219.0928, 163.0502, and
145.0396 were detected, according to the HRMS2 spectrum of
the parent compound, indicating unchanged fluoro butyl
and indazole parts. Therefore, MB13 was hydroxylated
at the tert-butyl group. In case of MB14, the FIs at m/z
253.0983, 235.0877, 179.0451, and 161.0346 represented
the aforementioned FIs shifted by +15.9949 u (oxygen),
indicating that the indazole part of MB14 was hydroxylated,
but the exact position could not be determined based on the
fragmentation pattern.
The PI at m/z 348.1718 of MB6 (C18H23O3N3F
+) provided
a mass shift of −2.0157 u regarding the PI of MB8 (ester
hydrolysis). This was postulated to be an ester hydrolysis followed
by dehydrogenation (Haschimi et al., 2019; Krotulski et al.,
2019). Another possibility would be the formation of a lactone
after hydroxylation of the tert-butyl part, with or without
former ester hydrolysis as postulated for MDMB-FUBINACA
(Kavanagh et al., 2017). The formation of the lactone was
expected to be more likely due to the FI at m/z 320.1769
(C17H23O2N3F
+), which was also detected for MB13 (ester
hydrolysis + hydroxylation of the tert-butyl part) and MB16
(hydroxylation of the tert-butyl part), but not MB8 (ester
hydrolysis), and the FI at m/z 113.0597 (C6H9O
+
2 ), a 4,4-
dimethyl-2-oxotetrahydrofuran-3-ylium ion, formed by cleavage
of the bond between amide nitrogen and alpha carbon of the
lactone part. In accordance with the observations of Kavanagh
et al. (2017), MB6 was not ionizable in negative ionization mode,
which contrasts with the characteristic behavior of carboxylic
acids such as MB8 (ester hydrolysis).
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FIGURE 2 | HRMS2 spectra of 4F-MDMB-BINACA and some of its metabolites detected in incubations with pooled human liver S9 fraction, HepaRG cells, and/or
zebrafish larvae. Metabolite IDs correspond to Table 1. MB, 4F-MDMB-BINACA metabolite; RT, retention time.
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TABLE 1 | Absolute peak areas of 4F-MDMB-BINACA and its phase I and II metabolites in incubations with pooled human liver S9 fraction (pHLS9, n = 2), HepaRG cells
(n = 3), and zebrafish larvae (n = 3) taken from one replicate, each, along with the unique metabolite ID, observed metabolic reaction, and calculated exact mass.
Metabolite
ID














- (parent compound) 364.2031 9.37E+08 2.17E+08 1.28E+08 5.18E+08 2.89E+09
MB1 Amide hydrolysis 237.1034 n.d. n.d. 3.34E+04 3.82E+06 n.d.
MB2 Lactone formation + N-dealkylation 274.1186 n.d. n.d. n.d. n.d. 5.13E+05
MB3 Ester hydrolysis + N-dealkylation 276.1343 9.07E+05 1.27E+06 3.99E+05 6.92E+06 n.d.
MB4 N-Dealkylation 290.1499 5.62E+06 2.82E+05 n.d. 9.55E+06 7.45E+06
MB5 Lactone formation + oxidative defluorination 346.1761 n.d. 1.26E+06 n.d. 2.40E+05 9.42E+05
MB6 Lactone formation 348.1718 n.d. 5.21E+07 n.d. 2.48E+06 1.29E+08
MB7 Ester hydrolysis + oxidative defluorination 348.1918 n.d. 1.91E+06 1.25E+06 1.34E+07 5.96E+04
MB8 Ester hydrolysis 350.1874 1.01E+08 2.77E+08 5.16E+07 1.63E+09 1.73E+07
MB9 Lactone formation + oxidative defluorination +
oxidation to carboxylic acid
360.1554 n.d. 1.57E+05 n.d. n.d. 2.53E+06
MB10 Ester hydrolysis + oxidative defluorination + oxidation
to carboxylic acid
362.1710 n.d. n.d. 1.68E+05 8.32E+05 5.72E+04
MB11 Oxidative defluorination 362.2074 4.27E+06 3.89E+05 9.30E+04 6.93E+06 2.92E+06
MB12 Lactone formation + hydroxylation of the tert-butyl part 364.1667 n.d. n.d. n.d. n.d. 1.68E+06
MB13 Ester hydrolysis + hydroxylation of the tert-butyl part 366.1824 7.30E+03 6.42E+05 n.d. 3.13E+07 4.57E+05
MB14 Ester hydrolysis + hydroxylation of the indazole part 366.1824 4.94E+04 3.04E+05 n.d. n.d. n.d.
MB15 Oxidative defluorination + oxidation to carboxylic acid 376.1867 2.16E+06 3.34E+06 1.15E+04 8.00E+06 2.60E+07
MB16 Hydroxylation of the tert-butyl part 380.1980 1.70E+05 n.d. n.d. n.d. 5.98E+06
MB17 Hydroxylation of the butyl chain 380.1980 9.01E+05 5.84E+04 n.d. 2.95E+06 n.d.
MB18 Hydroxylation of the indazole part isomer 1 380.1980 3.75E+05 n.d. n.d. n.d. 4.77E+05
MB19 Hydroxylation of the indazole part isomer 2 380.1980 7.16E+06 4.56E+04 n.d. n.d. n.d.
MB20 Hydroxylation of the indazole part + sulfation 460.1548 n.d. n.d. n.d. n.d. 2.06E+06
MB21 Ester hydrolysis + oxidative defluorination +
glucuronidation
524.2239 n.d. n.d. 4.18E+05 7.56E+05 n.d.
MB22 Ester hydrolysis +
glucuronidation
526.2196 n.d. n.d. 2.56E+07 3.25E+07 n.d.
MB23 Ester hydrolysis + hydroxylation of the indazole part +
glucuronidation
542.2144 n.d. 1.34E+05 n.d. n.d. n.d.
MB24 Oxidative defluorination + oxidation to carboxylic acid
+ glucuronidation
552.2188 n.d. n.d. n.d. n.d. 2.34E+05
MB25 Hydroxylation of the tert-butyl part + glucuronidation 556.2301 n.d. n.d. n.d. n.d. 1.75E+07
MB26 Hydroxylation of the indazole part + glucuronidation 556.2301 5.96E+05 7.68E+05 n.d. 1.48E+06 1.96E+06
The five largest areas per model are given in bold. MB, 4F-MDMB-BINACA metabolite; n.d., not detected.
Glucuronidation was identified by the increase of 176.0320 u
(C6H8O6) in the parent mass. MB23 with the PI atm/z 542.2144
(C24H33O10N3F
+) was identified as product of ester hydrolysis,
hydroxylation of the indazole part, and glucuronidation. MB14
represented the corresponding phase I metabolite. MB14 and
MB23 provided the same fragmentation pattern below m/z
366.1824 (PI of MB14), but differences in the abundance of
several FIs. The FI at m/z 496.2089 (C23H31O8N3F
+) in the
HRMS2 spectrum of MB23 represented the FI at m/z 320.1769
(C17H23O2N3F
+) conjugated with glucuronic acid. Therefore,
the glucuronic acid moiety was most likely bound to the hydroxy
group at the indazole part and not to the carboxylic acid.
According to the recommendation of Richter et al., two
incubation time points were analyzed to detect initial metabolic
steps as well as late phase metabolites (Richter et al., 2017b).
As no reference standards of the metabolites were available,
their quantification was not possible. Only their abundance
could be compared to each other. However, it must be noticed
that the highest concentration is not always reflected by the
highest abundance, which is influenced by the ionizability of a
compound. Themost abundant metabolite in pHLS9 incubations
after 1 and 6 h was MB8 (ester hydrolysis). After 1 h of
incubation, it was followed by MB19 (hydroxylation of the
indazole part isomer 2) and MB4 (N-dealkylation). After 6 h
of incubation, MB6 (lactone formation) and MB15 (oxidative
defluorination + oxidation to carboxylic acid) represented the
second and third most abundant metabolites, respectively.
Incubations with pHLS9 following the same procedure were
already performed for 3,4-DMA-NBOMe, ephylone, 4F-PHP,
and 1P-LSD, and the results and their fragmentation patterns
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TABLE 2 | Number of phase I and II metabolites of the five tested NPS detected











Phase I 15 7 12 14
Phase II 2 2 3 4
3,4-DMA-NBOMe
Phase I 6
(Caspar et al., 2018b)
6 10 9
Phase II 5




(Wagmann et al., 2019b)
2 4 5
Phase II 8




(Wagmann et al., 2019b)
5 6 8
Phase II 2




(Wagmann et al., 2019c)
14 15 22
Phase II 0
(Wagmann et al., 2019c)
1 2 3
Total
Phase I 40 34 47 58
Phase II 17 11 19 21
were described elsewhere (Caspar et al., 2018b; Wagmann et al.,
2019b,c).
In vivo Maximum-Tolerated Concentration
Studies in Zebrafish Larvae
To exclude toxic effects of the investigated NPS on zebrafish
larvae, which might prevent metabolic transformations, the
MTC was evaluated. The survival rates of zebrafish larvae
(4 dpf) after 24-h treatment with the NPS added to the
medium at the concentrations of 0, 0.01, 0.1, 1, 10, 50,
or 100µM are given in Table 3. In case of 3,4-DMA-
NBOMe, ephylone, 4F-PHP, and 1P-LSD, survival rates were
100% for all tested concentrations and no malformations
were observed. Therefore, a concentration of 100µM was
considered to be non-toxic for zebrafish larva 4 dpf and
chosen for metabolism studies. The MTC study with 4F-
MDMB-BINACA showed survival rates of 73% and 53% at 50
and 100µM, respectively. No malformations were observed.
Further zebrafish studies were performed with only 25µM
4F-MDMB-BINACA, and larvae were monitored in terms
of survival and malformations, to ensure nontoxicity of the
chosen concentration.
TABLE 3 | Survival rates of zebrafish larvae (4 dpf) after 24-h treatment with
various concentrations of 3,4-DMA-NBOMe, ephylone, 4F-MDMB-BINACA,









0 100 100 100 100 100
0.01 100 100 100 100 100
0.1 100 100 100 100 100
1 100 100 100 100 100
10 100 100 100 100 100
50 100 100 73 100 100
100 100 100 53 100 100
Fifteen larvae were tested per concentration level and test compound, respectively.
Identification of Metabolites in Incubations
With HepaRG Cells and Zebrafish Larvae
and Comparison to Metabolites Identified
in Incubations With pHLS9
Zebrafish were found to have similar metabolic enzymes
to mammals and to be able to perform both phase I (such
as oxidations, N-demethylations, O-demethylations, or N-
dealkylations) and phase II metabolic reactions (for example,
sulfations, glucuronidations, or methylations) (De Souza
Anselmo et al., 2017; Matos et al., 2019). As whole organisms,
zebrafish larvae may also overcome the limitations of in vitro
model systems (Van Wijk et al., 2016). Concerning in vitro
metabolism studies, human liver tissue-derived primary
hepatocytes are considered as “gold standard,” but provide
several disadvantages such as complex isolation procedures, high
variability in the enzyme expression, and limited availability
(Guillouzo et al., 2007; Godoy et al., 2013). Relevant alternative in
vitro systems are sought after and especially HepaRG cells were
found to be a suitable alternative to primary human hepatocytes
(Lubberstedt et al., 2011; Godoy et al., 2013).
HepaRG cells represent immortalized human liver cells
derived from a tumor. They were shown to remain capable of
expressing most of the liver-specific functions, including the
major CYPs involved in drug metabolism, but were derived from
a CYP2D6 poor metabolizer patient (Guillouzo et al., 2007).
Neither HepaRG cells nor zebrafish larvae experiments demand
the supplementation of co-substrates of metabolic reactions
representing their main advantage over pHLS9 incubations
(Richter et al., 2017a). However, handling of cells as well
as zebrafish larvae is time-consuming and requires special
laboratory equipment and qualified personnel. Furthermore,
zebrafish larvae experiments required a higher total amount of
the NPS then HepaRG incubations. Incubations with pHLS9
could be performed with the lowest NPS amount, whichmight be
beneficial in cases only small volumes of substances are available.
Based on the results of the MTC study, a 4F-MDMB-
BINACA concentration of 25µM was added to the zebrafish
larvae medium and neither malformations nor dead larvae were
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observed after 24 h of incubation. Thus, 25µM 4F-MDMB-
BINACA was considered as non-toxic for zebrafish larvae (4
dpf). Focusing on the detection of metabolites, a previous study
demonstrated the extraction of zebrafish larvae to be superior
to the precipitation of the surrounding medium (Richter et al.,
2019a). In case of HepaRG cell incubations, the precipitated
cell culture medium was shown to be an appropriate matrix
for identification of metabolites (Richter et al., 2017a, 2019a,c).
HepaRG cell experiments were conducted using two different
concentrations (25 and 250µM, respectively) in accordance with
a previous study (Richter et al., 2019c). All tentatively identified
metabolites of 4F-MDMB-BINACA along with their absolute
peak areas in HepaRG cells incubations or zebrafish larvae are
listed in Table 1. The given areas were taken from one replicate of
the HepaRG incubations (n = 3) or zebrafish larvae experiments
(n = 3). The other replicates provided the same pattern of
metabolite abundances. HRMS2 spectra of the parent compound
and the metabolites are depicted in Figure 2 or Figure S1 in
the ESM.
Nine metabolites (7 phase I, 2 phase II) were detected in
the HepaRG cell culture medium using a 4F-MDMB-BINACA
concentration of 25µM and 15 metabolites (12 phase I, 3
phase II) were detected using 250µM 4F-MDMB-BINACA (see
Table 2). All metabolites identified after administration of 25µM
4F-MDMB-BINACA toHepaRG cells could also be detected after
administration of 250µM as well as six additional metabolites.
Most abundant metabolites wereMB8 (ester hydrolysis) followed
by MB7 (ester hydrolysis + oxidative defluorination) and MB22
(ester hydrolysis + glucuronidation). Eighteen metabolites (14
phase I, 4 phase II) were detected in zebrafish larvae (see
Table 2). MB8 (ester hydrolysis), MB6 (lactone formation),
and MB15 (oxidative defluorination + oxidation to carboxylic
acid) provided the highest abundance. In conclusion, zebrafish
larvae led to the identification of the highest number of 4F-
MDMB-BINACA metabolites among the investigated models.
In comparison to HepaRG cells, zebrafish larvae produced
more phase I, but also II metabolites. Incubations with pHLS9
produced one phase I metabolite more but two phase II
metabolites less than zebrafish larvae.
All tentatively identified metabolites of 3,4-DMA-NBOMe,
ephylone, 4F-PHP, and 1P-LSD in HepaRG cell incubations and
zebrafish larvae are listed in Tables S1–S4 (ESM), which also
contain the metabolites detected in pHLS9 incubations described
in literature. Detailed information on their MS fragmentation
patterns may also be found in literature (Caspar et al., 2018b;
Wagmann et al., 2019b,c). HRMS2 spectra of the parent
compounds and the metabolites recorded during the current
study are depicted in Figures S2–S5 (ESM). In accordance
with the results for 4F-MDMB-BINACA, zebrafish larvae also
produced the highest number of phase I and II metabolites
of 4F-PHP and 1P-LSD. Concerning 3,4-DMA-NBOMe, most
metabolites were formed by HepaRG cells with 250µM substrate
concentration, while pHLS9 incubations produced the highest
number of ephylone metabolites.
Summarizing the results of all five investigated NPS (see
Table 2), the highest number of metabolites could be detected
in zebrafish larvae (79 metabolites in total, 58 phase I, 21
phase II). However, some metabolites were exclusively formed
by zebrafish larvae (e.g., MB2, MB12, MN9, and MP3), possibly
indicating species differences between humans and zebrafish.
HepaRG cells after administration of 250µM substrate were
identified as the second most efficient metabolizing model (66
metabolites in total, 47 phase I, 19 phase II), followed by
pHLS9 incubations (57 metabolites in total, 40 phase I, 17
phase II). In the current study, HepaRG cells produced more
metabolites after application of 250µM NPS in comparison to
25µM. However, as the investigated NPS were not tested for
toxicity in HepaRG cells prior to the experiments, incubation
of two different concentrations is also recommended for
future studies.
Monooxygenases Activity Screening of
4F-MDMB-BINACA
The involvement of monooxygenases in the metabolic phase
I transformations of 4F-MDMB-BINACA was elucidated using
single-enzyme incubations. Single-enzyme incubations allowed
the evaluation of the involvement of an individual isoform, which
is important to assess the risk of interindividual differences based
on polymorphisms or interactions with co-consumed drugs
(of abuse) or food ingredients due to inhibition or induction
(Meyer, 2016). Ten different CYP isoenzymes and FMO3 were
used representing monooxygenases known to be involved in
the human hepatic metabolism of xenobiotics (Wagmann et al.,
2016). Incubations with pHLM, containing all these isozymes
in their natural composition, were used as positive controls.
Results are given in Table 4. The initial monooxygenases
activity screenings of 3,4-DMA-NBOMe, ephylone, 4F-PHP,
and 1P-LSD were described elsewhere (Caspar et al., 2018a;
Wagmann et al., 2019b,c). CYP3A4 was described to be
involved in the N-dealkylation and CYP2C19 and CYP2D6 in
the O-demethylation and hydroxylation of 3,4-DMA-NBOMe
(Caspar et al., 2018a; Wagmann et al., 2019b,c). Ephylone
and 4F-PHP were both metabolized by CYP1A2, CYP2B6,
CYP2C19, and CYP3A4 (Caspar et al., 2018a; Wagmann et al.,
2019b,c), while 1P-LSD was N-dealkylated and hydroxylated
exclusively by CYP3A4 (Caspar et al., 2018a; Wagmann et al.,
2019b,c).
CYP1A2, CYP2C8, CYP2C19, CYP3A4, and CYP3A5
were shown to be involved in the metabolic phase I
reactions of 4F-MDMB-BINACA. CYP3A5 was involved
in all observed metabolic steps with the exception of the
amide hydrolysis (MB1) and the ester hydrolysis (MB8).
Both hydrolysis steps were found to be not catalyzed by
the investigated monooxygenases but, interestingly, only
detected in pHLM incubations. The elimination of the fluoro
butyl chain (MB4) was catalyzed by CYP1A2, CYP2C19,
CYP3A4, and CYP3A5. The lactone formation (MB6) was
catalyzed by CYP3A4 and CYP3A5, demonstrating that
previous ester hydrolysis was not essential for formation
of MB6. The oxidative defluorination (MB11) was detected
in incubations with CYP2C8 and CYP3A5. Hydroxylated
metabolites (MB16–MB19) were formed by CYP1A2, CYP2C19,
CYP3A4, and CYP3A5. Due to the high number of CYP
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TABLE 5 | Detection of the 4F-MDMB-BINACA metabolites after amide hydrolysis
(MB1) or ester hydrolysis (MB8, metabolite IDs correspond to Table 1) in in vitro
incubations containing one out of three human carboxylesterase isozymes (hCES),
respectively, pooled human liver microsomes (pHLM), pooled human liver S9
fraction (pHLS9), or pooled human blood plasma (pHBP).








Incubations were performed in duplicate; +, detected; –, not detected.
isozymes found to be involved in the phase I metabolism,
it is unlikely that polymorphisms or inhibition of a single
isozyme will have a high impact on the biotransformation of
4F-MDMB-BINACA in vivo.
Esterase Activity Screening of
4F-MDMB-BINACA
In order to investigate the involvement of esterases in
the metabolism of 4F-MDMB-BINACA, an esterase activity
screening was performed using three recombinant human
carboxylesterases, pHLM, pHLS9, and pooled human blood
plasma. The results are listed in Table 5. Carboxylesterases
are membrane-bound phase I drug-metabolizing enzymes
that can hydrolyze a variety of xenobiotics (Wang et al.,
2011). Ester hydrolysis of 4F-MDMB-BINACA (MB8) was
shown to be catalyzed by hCES1b and hCES1c. This was
consistent with a previous study by Meyer et al., describing
that drugs of abuse with small alcohol parts were mainly
hydrolyzed by hCES1 isoforms (Meyer et al., 2015). Amide
hydrolysis (MB1) was shown to be catalyzed by hCES1c.
MB1 and MB8 were also detected in incubations with
pHLM and pHLS9, but not in incubations with pooled
human blood plasma. The human liver preparations of
pHLM and pHLS9 are known to contain carboxylesterases,
mainly hCES1 isoforms, but also hCES2 in lower levels
(Wang et al., 2011). Pooled human blood plasma contains
no carboxylesterases, but the four non-specific esterases such
as butyrylcholinesterase, paraoxonase, acetylcholinesterase, and
albumin esterase (Li et al., 2005). MB1 was not identified
in the prior pHLS9 incubations for identification of phase
I and II metabolites of 4F-MDMB-BINACA. This was most
probably caused by low formation levels of MB1 in these
incubations due to the predominance of other metabolic
pathways. Genetic polymorphisms of hCES1 have been shown
to affect the metabolism of several drugs (Di, 2019). Therefore,
interindividual differences in the hydrolysis of 4F-MDMB-
BINACA cannot be excluded.
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Comparison to Metabolites Identified in
Human Biosamples
Zebrafish larvae were identified as a model system producing
the highest number of metabolites of the five investigated NPS.
However, a high number of metabolites does not necessarily
mean that a model system is the most suitable one for developing
analytical procedures for human biosamples. The metabolites
identified during a metabolism study must be implemented
in screening procedures for human biosamples aiming to
detect the intake of NPS for example in a clinical or forensic
toxicological context. The consideration of metabolites as targets
is crucial particularly in urine screening (Wagmann and Maurer,
2018), but the detection of NPS can only be successful if the
implemented metabolites were the same as the ones present
in human biosamples. The implementation should not be
motivated by the abundance of the metabolite. Each model
system has limitations and a minor metabolite detected in a
model system may be a major metabolite in humans. Metabolites
tentatively identified in pHLS9, HepaRG cells, and zebrafish
larvae incubations were compared to those detected in human
biosamples to determine the measure of concordance.
Human blood and urine samples of a male individual after
suspected intake of drugs of abuse were submitted to the
authors’ laboratory for regular toxicological analysis. The patient
was initially found unconscious and taken to the hospital.
A comprehensive toxicological screening in plasma and urine
was performed including numerous therapeutic drugs, drugs of
abuse, NPS, and their metabolites. The toxicological screening
detected not only 4F-MDMB-BINACA but also amitriptyline
and quetiapine at therapeutic levels in the patient’s biosamples.
No targeted analysis for detection of γ-hydroxybutyrate (GHB),
which would also be able to cause deep sedation, was performed
due to the patient’s symptoms and the case history.
The reconstructed chromatograms of the m/z of 4F-MDMB-
BINACA and its metabolites derived from the HR full scan of
the plasma and urine sample analysis are given in Figure 3.
The most abundant signals in descending order in the plasma
sample were assigned to the parent compound 4F-MDMB-
BINACA, MB8 (ester hydrolysis), MB6 (lactone formation),
and MB16 (hydroxylation of the tert-butyl part). Time point
and dosage of the 4F-MDMB-BINACA intake were unknown,
but the presence of the parent compound and the patient’s
FIGURE 3 | Reconstructed chromatograms of the mass-to-charge ratios of 4F-MDMB-BINACA and its metabolites in high-resolution full scan derived from an
authentic human plasma and urine sample after unknown dose and time point of 4F-MDMB-BINACA intake. Colored figure may be viewed online.
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TABLE 6 | Relative number of matches (%) with the four most abundant signals
detected in human plasma and urine samples after intake of 4F-MDMB-BINACA,
ephylone, or 4F-PHP compared to incubations with pooled human liver S9










Plasma 100 50 75 100
Urine 75 50 100 75
Ephylone (Wagmann et al., 2019b)
Plasma 100 75 100 100
Urine 100 75 100 100
4F-PHP (Wagmann et al., 2019b)
Plasma 75 50 50 100
Urine 75 25 50 75
Total 88 54 79 92
health status suggested a recent intake. The most abundant
signals in the urine sample were assigned to MB22 (ester
hydrolysis + glucuronidation), MB13 (ester hydrolysis +
hydroxylation of the tert-butyl part), MB6 (lactone formation),
and MB8 (ester hydrolysis). However, the parent compound was
barely detectable in urine. Therefore, MB6, MB8, and MB22
are particularly recommended as targets for comprehensive
screening procedures, if the sample preparation of urine does not
contain conjugate cleavage. Otherwise, MB22 does not have to be
included. The approaches used by Haschimi et al. and Krotulski
et al. included conjugate cleavage in urine and both only
described phase I metabolites of 4F-MDMB-BINACA (Haschimi
et al., 2019; Krotulski et al., 2019). Haschimi et al. identified 13
metabolites in 17 human urine samples and recommended MB6
and MB8 as reliable urinary markers (Haschimi et al., 2019).
Krotulski et al. identified nine 4F-MDMB-BINACA metabolites
in four blood and four urine samples and only recommended
to include MB8 as well as MB11 in toxicological screening
procedures (Krotulski et al., 2019).
Table 6 summarizes the concordance of the four most
abundant signals in the current patient’s plasma or urine with the
4F-MDMB-BINACA metabolites identified in pHLS9, HepaRG
cells, and zebrafish larvae experiments. Concerning plasma, all
four compounds reflecting the four most abundant signals were
detectable in pHLS9 incubations and zebrafish larvae (100%),
while only two (50%) or three compounds (75%) were detectable
in HepaRG cell experiments depending on the used NPS
concentration. HepaRG cells with 250µM 4F-MDMB-BINACA
formed all fourmost abundantmetabolites in urine (100%), while
pHLS9 and zebrafish larvae formed three metabolites (75%) and
HepaRG with 25µM 4F-MDMB-BINACA formed only two of
them (50%). These findings were in accordance with the previous
study focusing on another synthetic cannabinoid. Richter et al.
reported HepaRG cells to form the highest number of the most
abundant human urinary metabolites of 7′N-5F-ADB, followed
by zebrafish larvae and pHLS9 incubations (Richter et al., 2019a).
Data concerning detectability of ephylone and 4F-PHP in
human biosamples were also available and taken from a recent
publication (Wagmann et al., 2019b). Ephylone, ME1 (N-
deethylation), ME2 (demethylenation), ME3/4 (demethylenation
+ methylation), as well as the corresponding glucuronic
acid conjugates of ME2 (ME11/12) and ME3/4 (ME13/14)
represented the highest ephylone-related signals in human
plasma and/or urine. In case of 4F-PHP, the parent compound,
MP2 (reduction), MP3 and MP4 (hydroxylation + oxidation
to ketone or lactam), and MP10 (reduction + glucuronidation)
led to the signals with the highest abundance (Wagmann
et al., 2019b). As given in Table 6, pHLS9, HepaRG cells
with 250µM NPS, and zebrafish larvae experiments provided
perfect agreement with the four most abundant ephylone-
related signals in plasma and urine (100%). Zebrafish larvae
experiments were also perfectly suited for detection of the
four most abundant 4F-PHP-related signals in human plasma
(100%). The accordance with human urine was the same for
pHLS9 and zebrafish larvae experiments, but both models only
led to the detection of three out of the four most abundant
signals (75%). Overall, zebrafish larvae experiments provided
the most comprehensive concordance of detected NPS-related
compounds with those present in the human biosamples plasma
and urine (92%). Incubations with pHLS9 came as second best
(88%) followed by HepaRG cell incubations with 250µM NPS
(79%). These findings underline the suitability of zebrafish
larvae for toxicokinetic studies of NPS. As zebrafish larvae
represent intact organisms, their possible application is beyond
metabolism studies, e.g., investigations on distribution or
excretion patterns of NPS. However, the most easily manageable
model investigated in this study, the pHLS9 incubations, also
provided a good overlap with metabolites detected in human
biosamples and can also be considered as an appropriate
in vitro metabolism model for developing toxicological
screening procedures.
Unfortunately, only very limited data concerning detectability
of 3,4-DMA-NBOMe and 1P-LSD in human biosamples were
available. Nevertheless, Caspar et al. recommended 3,4-DMA-
NBOMe after O-demethylation (MN5 or MN6) or O,O-
didemethylation (MN2) of the amphetamine part as well as their
glucuronides (MN20 or MN21 and MN17) as urine screening
targets for 3,4-DMA-NBOMe after oral application to rats.
HepaRG cells and zebrafish larvae produce MN5, MN6, MN20,
andMN21, while Caspar et al. only detected one isomer (MN5 or
MN6 and MN20 or MN21), but also MN2 and MN17 in pHLS9
incubations (Caspar et al., 2018b).
It is likely that 1P-LSD is hydrolyzed to LSD in vivo (Brandt
et al., 2016; Grumann et al., 2019; Halberstadt et al., 2019;
Wagmann et al., 2019c). Grumann et al. reported that 1P-
LSD could not be detected in serum and urine samples of
an intoxicated patient after assumed consumption of a blotter
containing 1P-LSD. However, they were able to find LSD in
both matrices, but no information on the presence of 1P-LSD-
specific metabolites in the biosamples was given (Grumann
et al., 2019). Halberstadt et al. were able to detect 1P-LSD,
LSD, and several metabolites in rat plasma after subcutaneous
administration to rats. Some metabolites were found to be
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1P-LSD specific as they still contained the 1-propionyl moiety
(Halberstadt et al., 2019).
Finally, some limitations of the present study must be
considered. First, only biosamples of one individual after intake
of 4F-MDMB-BINACA or ephylone and 4F-PHP were used for
comparison and interindividual metabolism differences cannot
be excluded. The same is true for species differences between
humans and zebrafish concerning the metabolism of 3,4-DMA-
NBOMe and 1P-LSD, as human biosamples were not available.
In addition, different NPS concentrations were used for the
different metabolism models based on experience and MTC
study results.
CONCLUSIONS
The three metabolism models, by name pHLS9 incubations,
HepaRG cells, and zebrafish larvae, formed numerous
metabolites of the five NPS. Zebrafish larvae were found
to produce the highest number of metabolites. The 4F-
MDMB-BINACA, ephylone, and 4F-PHP metabolites formed
by zebrafish larvae also provided the highest concordance
with the four most abundant signals in human biosamples.
Nevertheless, all metabolism models produced metabolites
similar to those detected in authentic biosamples. Furthermore,
several CYP isozymes as well as hCES1b and hCES1c were
shown to be involved in the phase I metabolic reactions of
4F-MDMB-BINACA. Interindividual differences, presumably
mainly based on hCES1 polymorphisms, cannot be excluded.
The current study underlines the potential of zebrafish
larvae as a tool for elucidating the toxicokinetics of NPS in
the future.
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